BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080 [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069]
URL: https://www.wjgnet.com/1948-5182/full/v27/i47/8069.htm
Number Citing Articles
1
Qiao Ke, Fuli Xin, Huipeng Fang, Yongyi Zeng, Lei Wang, Jingfeng Liu. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic ReviewFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.913464
2
Qianyi Lin, Dexiong Chen, Kangde Li, Xiaomin Fan, Qi Cai, Weihong Lin, Chunhong Qin, Tao He. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality TherapyFrontiers in Radiology 2022; 2 doi: 10.3389/fradi.2022.858963
3
Renguo Guan, Chengyou Yu, Shaohua Li, Jie Mei, Wei Wei, Rongping Guo. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinomaFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.998534
4
Jing-Nan Xue, Yan-Yu Wang, Yun-Chao Wang, Nan Zhang, Long-Hao Zhang, Zheng-Hui Lu, Li-Jin Zhao, Hai-Tao Zhao. Novel cellular therapies for hepatobiliary malignanciesHepatobiliary & Pancreatic Diseases International 2022; 21(5): 450 doi: 10.1016/j.hbpd.2022.08.014
5
Kang Chen, Cheng-Piao Luo, De-Xiang Ge, Ke-Lin Wang, Qin Luo, Yan-Zhi Li, Xue-Mei You, Bang-De Xiang, Le-Qun Li, Liang Ma, Jian-Hong Zhong. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinomaFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.946693
6
Bowen Chen, Jin Lei, Haitao Zhao, Jinghui Dong, Zhen Zeng, Yinyin Li, Lingxiang Yu, Lin Zhou, Aiying Jia, Yinying Lu, Jiamin Cheng. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective StudyJournal of Hepatocellular Carcinoma 2022; : 1171 doi: 10.2147/JHC.S387254
7
Qingwei Zhu, Wei Rao, Junyu Huo, Zixiang Li, Song Wang, Wensheng Qiu, Ge Guan, Yang Xin, Ning Fan, Jinzhen Cai, Liqun Wu. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single centerBMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02661-2
8
Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular CarcinomasAnnals of Surgical Oncology 2022; 29(13): 8436 doi: 10.1245/s10434-022-12495-z
9
Haoyang Bei, Weiheng Mai, Weifeng Chen, Mingyi Li, Yongguang Yang. Application of systemic treatment in conversion therapy options for liver cancerFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.966821
10
Haowen Tang, Yinbiao Cao, Yiping Jian, Xuerui Li, Junfeng Li, Wenwen Zhang, Tao Wan, Zhe Liu, Wei Tang, Shichun Lu. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A reviewBioScience Trends 2022; 16(2): 130 doi: 10.5582/bst.2022.01019